• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    4/29/26 4:15:11 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PAVS alert in real time by email
    6-K 1 pavs_6k.htm FORM 6-K pavs_6k.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of April 2026

     

    PARANOVUS ENTERTAINMENT TECHNOLOGY LTD.

    (Exact name of registrant as specified in its charter)

     

    250 Park Avenue, 7th Floor

    New York, NY 10017

    (Address of Principal Executive Office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form40-F.

     

    Form 20-F ☒      Form 40-F ☐

     

     

     

     

    Submission of Matters to a Vote of Security Holders.

     

    Paranovus Entertainment Technology Ltd. (the “Company”) held an extraordinary meeting of shareholders (“EGM”) at 10:00 a.m. ET on April 28, 2026 at its principal executive offices in 250 Park Avenue, 7th Floor, New York, NY 10017. Shareholders of Class A and Class B ordinary shares voted by proxy or at the meeting. There were shareholders of 67.12% out of a total votes of 1,024,784 Class A ordinary shares (representing 1,024,784 votes) and 23,846 Class B ordinary shares (representing 1,907,680 votes) and therefore constituting a quorum of more than one third of the shares outstanding and entitled to vote at the meeting as of the record date of April 7, 2026. Each Class A ordinary share is entitled to one (1) vote, and each Class B ordinary share is entitled to eighty (80) votes. The final voting results for each matter submitted to a vote of shareholders at the meeting are as follows:

     

    1.

    as an ordinary resolution to increase the share capital of the Company from:

     

    US$3,400.50 divided into 279,166,666 Class A ordinary shares of US$0.000012 par value each and 4,166,666 Class B ordinary shares of a par value of US $0.000012 each, and 41,666 preferred shares of a par value of US $0.000012 each,

     

    to:

     

    US$601,200.50 divided into 50,000,000,000 Class A ordinary shares of US$0.000012 par value each and 100,000,000 Class B ordinary shares of a par value of US $0.000012 each, and 41,666 preferred shares of a par value of US $0.000012 each,

     

    by creating additional 49,720,833,334 Class A ordinary shares, each with a par value of US $0.000012 and additional 95,833,334 Class B ordinary shares, each with a par value of US $0.000012 (the “Capital Increase” and such proposal, the “Capital Increase Proposal”)

     

    For

     

    Against

     

    Abstain

     

     

    1,951,328

     

    15,122

     

    1,893

     

     

     

    Accordingly, the Capital Increase Proposal has been approved.

     

     

    2.

    that as a special resolution to approve and adopt of the seventh amended and restated memorandum and articles of association (the “Seventh M&A”) in the form as attached to the proxy statement as Appendix A to reflect, inter alia, the Capital Increase and the Action by Written Resolutions of Members (as defined below), in substitution for the Sixth M&A. (the “Amendment to the Sixth M&A” and such proposal, the “Amended M&A Proposal”)

     

    For

    Against

    Abstain

     

     

    1,952,870

     

    12,737

     

    2,736

     

      

     

    Accordingly, the Amended M&A Proposal has been approved. 

     

     

    3.

    as an ordinary resolution:

     

    (a) that the Company effect one or more reverse share splits of its authorized, issued and outstanding share capital by way of consolidation (the “Share Consolidations”), such that the number of authorized, issued and outstanding shares is decreased by the applicable ratio and the par value of each authorized, issued and outstanding ordinary share is increased by the same ratio, as applicable, with each Share Consolidation to be effected at such time or times, and at a precise consolidation ratio or ratios, in each case as determined by the board of directors (the “Board”) in its absolute discretion within two (2) years following the date of the 2026 Extraordinary Meeting, provided that the cumulative consolidation ratio for all such Share Consolidations shall not exceed 1:5,000 in the aggregate (the “Consolidation Ratio Cap”).

     

    (b) no fractional ordinary shares of the Company be issued in connection with each of the Share Consolidations; if a shareholder is entitled to receive a fractional ordinary share upon a Share Consolidation, the total number of ordinary shares to be received by such shareholder be rounded up to the next whole ordinary shares.

     

    (c) the Board be authorized, at its absolute and sole discretion, to either (i) implement one or more Share Consolidations, and determine, at any time within two (2) years following the date of the 2026 Extraordinary Meeting and subject to the Consolidation Ratio Cap, the exact consolidation ratio and effective date of each such Share Consolidation; or (ii) elect not to implement any Share Consolidation during a period of two years of the date of the 2026 Extraordinary Meeting.

     

    (d) if and when deemed advisable by the Board in its sole discretion, any director or officer of the Company be authorized, for and on behalf of the company, to do all such other acts and things and execute all such documents necessary or desirable to implement the Share Consolidation(s) (the “Share Consolidation Proposal”).

      

     

    For

     

    Against

    Abstain

     

     

    1,950,281

     

    15,683

     

    2,379

     

     

    Accordingly, the Share Consolidation Proposal has been approved.  

     

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

    Paranovus Entertainment Technology Ltd.

     

     

     

     

     

    Date: April 29, 2026

    By:

    /s/ Xiaoyue Zhang

     

     

     

    Xiaoyue Zhang

    Chief Executive Officer

     

     

     

    3

      

    Get the next $PAVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PAVS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Xu Minzhu

    3 - Paranovus Entertainment Technology Ltd. (0001751876) (Issuer)

    4/6/26 2:07:10 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Xu George Yijian

    3 - Paranovus Entertainment Technology Ltd. (0001751876) (Issuer)

    3/20/26 2:23:50 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Guo Ling

    3 - Paranovus Entertainment Technology Ltd. (0001751876) (Issuer)

    3/20/26 2:23:24 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    SEC Filings

    View All

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    6-K - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    6/16/26 4:15:23 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B5 filed by Paranovus Entertainment Technology Ltd.

    424B5 - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    6/16/26 12:45:38 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    6-K - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    6/15/26 10:10:10 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PAVS Announces Pricing of a $10 Million Registered Direct Offering of Class A Ordinary Shares and Pre-Funded Warrants

    NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- PAVS (NASDAQ:PAVS) (the "Company"), a consumer products and digital commerce solutions company, today announced that it has entered into a definitive agreement with certain institutional investors for a registered direct offering of an aggregate of 50,000,000 Class A ordinary shares (or pre-funded warrants to purchase Class A ordinary shares in lieu thereof) at a purchase price of $0.20 per share. The gross proceeds to the Company from the offering are expected to be approximately $10 million, before deducting offering expenses. The offering is expected to close on or about June 16, 2026, subject to the satisfaction of customary closing conditio

    6/15/26 2:30:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Beyond Fast Fashion: Advanced Fibers and Smart Manufacturing Are Reshaping the Global Textile Industry

    DENVER, June 15, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – The textile and apparel sector is rarely considered one of the market's most exciting industries. Yet some of today's most intriguing innovation stories are emerging from companies seeking to transform how fabrics are produced, sourced, and utilized across global supply chains. From recombinant spider silk to direct-to-consumer activewear brands and expanding manufacturing capacity, a new generation of companies is positioning itself around themes that include sustainability, performance materials, advanced manufacturing, and next-generation consumer products. Investors searching for emerging opportunities are increasingl

    6/15/26 10:36:44 AM ET
    $GIII
    $JRSH
    $PAVS
    Apparel
    Consumer Discretionary
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Announces Pricing of $5 Million Registered Direct Offering At-The-Market Under NASDAQ Rules

    NEW YORK, March 24, 2026 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS) today announced that it has entered into a definitive agreement with a single institutional investor for a registered direct offering priced at-the-market under Nasdaq Rules of an aggregate of 14,285,715 Class A ordinary shares (or Class A ordinary share equivalents in lieu thereof) at a purchase price of $0.35 per share. The gross proceeds to the Company from the offering are expected to be approximately $5 million, before deducting placement agent commissions and other offering expenses. The offering is expected to close on or about March 25, 2026, subject to the satisfaction of customary clos

    3/24/26 3:09:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Financials

    Live finance-specific insights

    View All

    Paranovus Entertainment Technology Limited Regains Compliance with Nasdaq Minimum Bid Price Requirement

    NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS) today announced that on January 6, 2026, it received notification from the Nasdaq Office of General Counsel stating that the Company had regained compliance with the bid price requirement as set forth in Listing Rule 5550(a)(2) and that Company is therefore in compliance with the Nasdaq Capital Market's listing requirements. As a result, the scheduled hearing before the Hearings Panel on January 29, 2026 had been cancelled and the matter was closed. The Company's Class A ordinary shares will continue to be listed and traded on The Nasdaq Capital Market under the ticker "PAVS."

    1/9/26 8:45:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Received Nasdaq Delisting Notice

    NEW YORK, Dec. 22, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS), announced today that the Company received a letter from the Nasdaq Stock Market LLC ("Nasdaq") on December 17, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company's Class A ordinary shares from The Nasdaq Capital Market, because the Company failed to comply with the Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the "Rule"). As previously disclosed, on July 11, 2025, the Nasdaq staff notified the Company that the bid price of its listed Class A ordinary

    12/22/25 4:30:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Announces 1-For-100 Reverse Share Split

    NEW YORK, Dec. 16, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS), today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par value $0.01 per share (the "Class A Ordinary Shares"), at a ratio of 1-for-100, to be effective at the open of business on Thursday, December 18, 2025. Our Class A Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market ("Nasdaq") on Thursday, December 18, 2025. Following the reverse share split, the Class A Ordina

    12/16/25 9:00:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:56:47 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:56:31 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:55:36 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care